Japan Tobacco Inc.

Yoshihisa Koga

Masahiro Sakata

Shinji Yata

Yoshikazu Hori

Takayuki Yamasaki

Wataru Kondo

Takuya Matsuo

Masanori Shindo

Takashi Watanabe

Takeshi Nakamura

Tatsuya Matsumoto

Hidekazu Ozeki

To provide a compound having an excellent inhibitory effect on vanilloid receptor subtype 1 (VR1) activity which is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, neuralgia, etc. and a pharmaceutical composition containing the compound. The object has been attained by a condensed benzamide compound represented by the following formula (the symbols in the formula have the same meanings defined in the specification) or its salt: 

Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity

A 3,4-dihydrobenzoxazine compound of the present invention is represented by the following formula [1] (wherein X is a nitrogen atom or CR; Ris a hydrogen atom or a halogen atom; Ris a C1-6 alkoxy group which may be substituted with the same or different 1 to 5 substituents selected from a halogen atom and a hydroxyl group; and Ris a halogen atom. However, Ris a halogen atom when X is CR). This compound is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, etc. 

3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity

Therapeutic agent for osteoporosis and triazepine compound

Growing community of inventors

Takatsuki, Japan

Yoshihisa Koga